Neuroimaging of Mood Disorders

April 9, 2010
F. Andrew Kozel, MD, MSCR

Volume 27, Issue 4

Help in Clinical Decision Making

Although significant advances have been made in the treatment of mood disorders, how to individualize treatment is still not understood. Diagnoses in psychiatry are based on symptoms rather than on the causes of the disorder; thus, treatment decisions are based on choosing an intervention that works in patients with a particular group of symptoms and not necessarily on the pathology specific to an individual patient. This is not necessarily a problem except that a substantial percentage of patients with mood disorders do not achieve remission, even with optimal treatment.1,2 In fact, complete symptom remission is rare and recurrences are frequent-finding a successful treatment often takes multiple trials of various drugs.

During repeated attempts at finding successful treatment or during recurrences, patients may become demoralized, lose hope, and discontinue treatment. Prolonged mood symptoms increase the suffering, the morbidity and, potentially, the mortality associated with these disorders. An objective method to predict and understand treatment outcome is needed.3 In most clinical scenarios, the question is not whether the patient has a mood disorder but rather which treatment, if any, is most likely to enable the patient to achieve wellness.

Neuroimaging technologies

CT, MRI, diffusion tensor imaging (DTI), functional MRI (fMRI), magnetic resonance spectroscopy, positron emission tomography (PET), single photon emission CT (SPECT), and functional near-infrared spectroscopy (fNIRS) offer a noninvasive way to investigate the neurobiology associated with mood disorders. Unfortunately, because there are no neuropathological criteria that define mood disorders, no criteria exist to compare directly with neuroimaging findings. Thus, the neurobiology to be examined has to be defined in other ways.

One method by which neuroimaging could potentially help in clinical decision making would be to increase our understanding of the brain correlates of treatment. Identifying the neurobiology that can be used to predict a patient’s response to a particular treatment, as well as what changes occur with a successful treatment, would have profound clinical and scientific implications. A number of different strategies have been used to understand the brain characteristics that predict response and that correlate with successful outcome. (For a more detailed coverage of the literature, reviews of research using neuroimaging in mood disorders from several perspectives are available.4-8)

Brain correlates of treatment are often investigated by acquiring neuroimaging data on a group of patients (and sometimes healthy controls), treating the patients, and clinically determining which patients respond. In addition, neuroimaging data are often acquired after a specified treatment period. Responders and nonresponders are defined on the basis of clinical criteria. To determine neural correlates of treatment response, the pretreatment data are compared with the posttreatment data to determine changes in the 2 groups. These brain differences are then considered predictors of treatment response. This method has been used with various imaging modalities to investigate predictors of response and correlates of treatment response in patients whose condition is being treated with a variety of interventions (Table).

Neural correlates of response

Multiple reports of neurobiological differences in responders versus nonresponders, as well as brain changes with successful treatment, have been reported. Various researchers, however, have focused on different regions of the brain. In their study on depression, Mayberg and colleagues9 concentrated on the anterior cingulate, especially the subgenu portion (Brodmann area 25).

Saxena and colleagues10 differentiated predictors of treatment response for major depressive disorder (MDD) and obsessive-compulsive disorder and found the amygdala and midline prefrontal regions to be important markers.

Siegel and colleagues11 used fMRI to predict outcome from cognitive-behavioral therapy and found that the subgenu of the anterior cingulate and amygdala were important structures.

Although brain differences associated with clinical response are regularly reported, the specific brain regions implicated are not consistent. Thus, a clear understanding of the neural correlates of predictors of response or the correlates of response has not emerged. The consistency of finding a significant difference in the brain of those who do and those who do not respond may be related to publication bias, because significant findings are more likely to be published than nonsignificant findings. The large number of studies that have found a difference, however, suggests that there are clear brain differences that predict treatment response and brain changes that are correlated to successful treatment.

Variable methodologies produce inconsistent results

Brain findings associated with predictors of treatment and with change with successful treatment may be related to the treatment used (eg, medications, psychotherapy, brain stimulation). In addition to treatment variability, the imaging techniques for measuring predictors of treatment and correlates of response are also quite varied. There is no universally agreed on method for acquiring and analyzing imaging data. Even within a particular imaging modality, the method of analysis can be quite different. The treatment modality used and the way the brain structure and/or function is measured could account for some of the variability in results.

CHECKPOINTS
? Currently, the only clinical role for neuroimaging in the evaluation of a patient with a mood disorder is to determine whether a neurological condition (eg, tumor, stroke, normal pressure hydrocephalus) may be contributing to the clinical picture. There is no scientifically validated role for neuroimaging to assist in choosing a particular treatment or to make a particular diagnosis in a patient who has a mood disorder.

? If a neuroimaging test can differentiate whether a patient with a depressive episode would respond to treatment A versus treatment B, it could have a significant effect on the patient’s evaluation, treatment, and outcome.

? Neuroimaging holds great promise in the evaluation of neurobiological predictors of treatment response and correlates of treatment outcome and thus in helping us to understand mood disorders in a clinically meaningful way.

 

Another problem is the fundamental assumption that each mood disorder-as diagnosed in DSM-IV using a syndrome-based approach-represents similar neuropathology. This is especially pertinent in neuroimaging research because the vast majority of neuroimaging studies obtain results from a “group analysis.” A group analysis involves averaging the data from multiple participants to have enough power to distinguish a difference. This is a consequence of the generally low signal to noise ratio of neuroimaging data. The essential assumption of a group analysis is that all the members of a group share the same neurobiology. There is growing evidence, however, that the neuropathology of mood disorders assessed with neuroimaging is not consistent.12 With the small sample sizes in neuroimaging studies, the group result can be especially sensitive to a small number of participants within that group (ie, a few participants can drive the result for the whole group). Thus, differences in results across studies may be related to differences in samples studied by the investigators.

Measuring the connectivity of brain circuits

Although there is a lack of consistency for specific brain regions, a majority of the findings associated with mood disorders involve the prefrontal and limbic regions. Initially, the focus was on the level of activation of a brain region either at rest or during a particular task (eg, is the dorsolateral prefrontal cortex more or less active?). There is, however, a growing interest in how different brain regions work together. Because the brain is made up of circuits, connectivity between different regions can be measured in various ways.

Connectivity can be directly measured intraoperatively during neurosurgery. Such measurements, however, are only available for a very small, restricted population with mood disorders (eg, patients undergoing neurosurgery for epilepsy, deep brain stimulation, or epidural brain stimulation). To study a broader sample of patients with a mood disorder in an ethical manner, several noninvasive methods of measuring connectivity in brain circuits are emerging.

One involves focal stimulation of the brain, measuring changes in multiple regions. These include interleaved repetitive transcranial magnetic stimulation (rTMS)/fMRI,13 rTMS/PET,14 rTMS/SPECT,15 and simultaneous rTMS/fNIRS.16 Each method has its own strengths and weaknesses, but all offer a unique opportunity to test the circuitry of the brain as it relates to predictors of treatment and correlates of outcome. These technologies are, however, still at the research stage of development.

In addition to noninvasive stimulation of the brain and measuring changes, connectivity of brain regions can be assessed using spontaneous brain activity. Spontaneous neuronal activity is not random “noise” but is important for various brain functions, and it may account for a significant portion of the brain’s metabolic energy.17,18

An important characteristic of this phenomenon is that functionally related regions exhibit coherence in their spontaneous neuronal activity.17 In addition, the degree of coherence in spontaneous neuronal activity can provide a measure of strength for a particular circuit.

These findings have led to the investigation of connectivity between brain regions during nontask periods.19,20 Alterations in connectivity as measured by fMRI have been used to study a number of psychiatric illnesses, including depression.21,22 The effect of antidepressants on connectivity measures for patients with MDD has also been investigated.23 Noninvasive measures of connectivity as well as coherence-based assessment of brain connectivity are exciting innovations that can improve our understanding of treatment response in mood disorders.

Diffusion tensor imaging

Another recently emerging noninvasive technology that is being used to assess brain connectivity is DTI. DTI uses the motion of water molecules to investigate the microstructure and organization of white matter tracts in the brain. This can provide a quantitative means to determine the integrity of anatomical connections between regions of the brain.24 DTI is beginning to be used to investigate normal white matter anatomy and disease states.

This technology has also been used to investigate the nature of white matter hyperintensities and to predict treatment response in geriatric depression.25,26 DTI has been combined with functional imaging (PET) to investigate connectivity in such neuropsychiatric disorders as schizophrenia.27 In addition to producing fractional anisotropy maps of regions, DTI can be used to trace white matter structures or tracts.28 Investigators are using the combination of information from fMRI with DTI tractography to better understand brain function.29 Although still only at the level of research development, DTI enables white matter and structural connectivity to be safely assessed.

Conclusion

Although neuroimaging offers tremendous potential for improving patient outcomes, its present level of development dictates that it should only be used as a research tool. Currently, the only clinical role for neuroimaging in the evaluation of a patient with a mood disorder is to determine whether a neurological condition (eg, tumor, stroke, normal pressure hydrocephalus) may be contributing to the clinical picture. There is no scientifically validated role for neuroimaging to assist in choosing a particular treatment or to make a particular diagnosis in a patient who has a mood disorder.

There are several characteristics that a neuroimaging diagnostic test must achieve in order to play a role in clinical practice (for a more complete discussion, see Hunter and colleagues30). Several of these characteristics, such as knowing the accuracy and variability of the result obtained in the population being tested, are shared by all diagnostic tests. There are several factors, however, that are unique to neuroimaging. As mentioned earlier, because of the low signal to noise ratio with most neuroimaging modalities, the majority of studies have relied on group level analysis. Because these are group studies, results from such studies cannot be applied to an individual. Clinically useful neuroimaging tests will have to provide valid results at the individual level.

When a diagnostic test moves from a research tool to a clinical tool, it is often much more broadly applied. This is an especially critical consideration in neuroimaging because the effect of a number of factors on neuroimaging results is not well understood. Factors such as age, sex, medication, medical illnesses, phase of menstrual cycle, and substance use may affect the accuracy and/or variability of the test result. Thus, neuroimaging diagnostic tests should only be applied to populations in which the test and testing conditions have been scientifically evaluated.

Diagnostic neuroimaging shares a requirement that is common to all medical diagnostic tests. That is, the test must provide added value in the care of the patient. A neuroimaging test that simply differentiates whether a patient is having a depressive episode or is healthy would not be especially helpful in most cases. Conversely, if a neuroimaging test can differentiate whether a patient with a depressive episode would respond to treatment A versus treatment B, then that test could have a significant effect on the patient’s evaluation, treatment, and outcome. Patients could forgo many attempts to find optimal therapy. Cost-effectiveness studies need to be undertaken as well, but the current high cost of morbidity and mortality from mood disorders leaves considerable room for cost savings-especially as they relate to quality-of-life measures and productivity.

The use of neuroimaging to evaluate the neurobiological predictors of treatment response and correlates of treatment outcome offers an exciting opportunity to better understand these disorders in a clinically meaningful way. This is especially true if neuroimaging were combined with other technologies, such as electroencephalography, binding of specific receptors, and genetics analysis, in an effort to understand treatment response in mood disorders.30-33 Although a scientifically valid neuroimaging test is not currently available for patients with mood disorders, the profound effect that such a test could have on clinical care dictates that more research is critically needed.

References:

References

1.

Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.

Am J Psychiatry.

2006;163:1905-1917.

2.

Perlis RH, Ostacher MJ, Patel JK, et al. Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD).

Am J Psychiatry.

2006;163:217-224.

3.

Hyman SE, Fenton WS. Medicine. What are the right targets for psychopharmacology?

Science.

2003;299:350-351.

4.

Mayberg HS. Modulating dysfunctional limbic-cortical circuits in depression: towards development of brain-based algorithms for diagnosis and optimised treatment.

Br Med Bull.

2003;65:193-207.

5.

Savitz J, Drevets WC. Bipolar and major depressive disorder: neuroimaging the developmental-degenerative divide.

Neurosci Biobehav Rev.

2009;33:699-771.

6.

Smith DF, Jakobsen S. Molecular tools for assessing human depression by positron emission tomography.

Eur Neuropsychopharmacol.

2009;19:611-628.

7.

Dougherty DD, Rauch SL. Brain correlates of antidepressant treatment outcome from neuroimaging studies in depression.

Psychiatr Clin North Am.

2007;30:91-103.

8.

Phillips ML, Travis MJ, Fagiolini A, Kupfer DJ. Medication effects in neuroimaging studies of bipolar disorder.

Am J Psychiatry.

2008;165:313-320.

9.

Mayberg HS, Brannan SK, Mahurin RK, et al. Cingulate function in depression: a potential predictor of treatment response.

Neuroreport.

1997;8:1057-1061.

10.

Saxena S, Brody AL, Ho ML, et al. Differential brain metabolic predictors of response to paroxetine in obsessive-compulsive disorder versus major depression.

Am J Psychiatry.

2003;160:522-532.

11.

Siegle GJ, Carter CS, Thase ME. Use of fMRI to predict recovery from unipolar depression with cognitive behavior therapy.

Am J Psychiatry.

2006;163:735-738.

12.

Fitzgerald PB, Laird AR, Maller J, Daskalakis ZJ. A meta-analytic study of changes in brain activation in depression.

Hum Brain Mapp.

2008;29:683-695.

13.

Li X, Nahas Z, Kozel FA, et al. Acute left prefrontal transcranial magnetic stimulation in depressed patients is associated with immediately increased activity in prefrontal cortical as well as subcortical regions.

Biol Psychiatry.

2004;55:882-890.

14.

Speer AM, Willis MW, Herscovitch P, et al. Intensity-dependent regional cerebral blood flow during 1-Hz repetitive transcranial magnetic stimulation (rTMS) in healthy volunteers studied with H215O positron emission tomography, II: Effects of prefrontal cortex rTMS.

Biol Psychiatry.

2003;54:826-832.

15.

Nahas Z, Stallings LE, Speer AM, et al. Perfusion SPECT studies of rTMS on blood flow in health and depression.

Biol Psychiatry.

1998;43:195. Abstract 63.

16.

Kozel FA, Tian F, Dhamne S, et al. Using simultaneous repetitive transcranial magnetic stimulation/functional near infrared spectroscopy (rTMS/fNIRS) to measure brain activation and connectivity.

Neuroimage.

2009;47:1177-1184.

17.

Fox MD, Raichle ME. Spontaneous fluctuations in brain activity observed with functional magnetic resonance imaging.

Nat Rev Neurosci.

2007;8:700-711.

18.

Raichle ME, Mintun MA. Brain work and brain imaging.

Annu Rev Neurosci.

2006;29:449-476.

19.

Biswal B, Yetkin FZ, Haughton VM, Hyde JS. Functional connectivity in the motor cortex of resting human brain using echo-planar MRI.

Magn Reson Med.

1995;34:537-541.

20.

Greicius MD, Krasnow B, Reiss AL, Menon V. Functional connectivity in the resting brain: a network analysis of the default mode hypothesis.

Proc Natl Acad Sci U S A.

2003;100:253-258.

21.

Greicius MD, Flores BH, Menon V, et al. Resting-state functional connectivity in major depression: abnormally increased contributions from subgenual cingulate cortex and thalamus.

Biol Psychiatry.

2007;62:429-437.

22.

Anand A, Li Y, Wang Y, et al. Activity and connectivity of brain mood regulating circuit in depression: a functional magnetic resonance study.

Biol Psychiatry.

2005;57:1079-1088.

23.

Anand A, Li Y, Wang Y, et al. Antidepressant effect on connectivity of the mood-regulating circuit: an fMRI study.

Neuropsychopharmacology.

2005;30:1334-1344.

24.

Lim KO, Helpern JA. Neuropsychiatric applications of DTI-a review.

NMR Biomed.

2002;15:587-593.

25.

Taylor WD, Payne ME, Krishnan KR, et al. Evidence of white matter tract disruption in MRI hyperintensities.

Biol Psychiatry.

2001;50:179-183.

26.

Alexopoulos GS, Kiosses DN, Choi SJ, et al. Frontal white matter microstructure and treatment response of late-life depression: a preliminary study.

Am J Psychiatry.

2002;159:1929-1932.

27.

Buchsbaum MS, Tang CY, Peled S, et al. MRI white matter diffusion anisotropy and PET metabolic rate in schizophrenia.

Neuroreport.

1998;9:425-430.

28.

Taylor WD, Hsu E, Krishnan KR, MacFall JR. Diffusion tensor imaging: background, potential, and utility in psychiatric research.

Biol Psychiatry.

2004;55:201-207.

29.

Greicius MD, Supekar K, Menon V, Dougherty RF. Resting-state functional connectivity reflects structural connectivity in the default mode network.

Cereb Cortex.

2009;19:72-78.

30.

Hunter AM, Cook IA, Leuchter AF. The promise of the quantitative electroencephalogram as a predictor of antidepressant treatment outcomes in major depressive disorder.

Psychiatr Clin North Am.

2007;30:105-124.

31.

Leuchter AF, Cook IA, Hunter A, Korb A. Use of clinical neurophysiology for the selection of medication in the treatment of major depressive disorder: the state of the evidence.

Clin EEG Neurosci.

2009;40:78-83.

32.

Miller JM, Oquendo MA, Ogden RT, et al. Serotonin transporter binding as a possible predictor of one-year remission in major depressive disorder.

J Psychiatr Res.

2008;42:1137-1144.

33.

Drago A, De Ronchi D, Serretti A. Pharmacogenetics of antidepressant response: an update.

Hum Genomics.

2009;3:257-274.

34.

Passero S, Nardini M, Battistini N. Regional cerebral blood flow changes following chronic administration of antidepressant drugs.

Prog Neuropsychopharmacol Biol Psychiatry.

1995;19:627-636.

35.

Mayberg HS, Brannan SK, Tekell JL, et al. Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response.

Biol Psychiatry.

2000;48:830-843.

36.

Pillay SS, Renshaw PF, Bonello CM, et al. A quantitative magnetic resonance imaging study of caudate and lenticular nucleus gray matter volume in primary unipolar major depression: relationship to treatment response and clinical severity.

Psychiatry Res.

1998;84:61-74.

37.

Brody AL, Saxena S, Silverman DH, et al. Brain metabolic changes in major depressive disorder from pre- to post-treatment with paroxetine.

Psychiatry Res.

1999;91:127-139.

38.

Konarski JZ, Kennedy SH, McIntyre RS, et al. Relationship between regional brain metabolism, illness severity and age in depressed subjects.

Psychiatry Res.

2007;155:203-210.

39.

Brockmann H, Zobel A, Joe A, et al. The value of HMPAO SPECT in predicting treatment response to citalopram in patients with major depression.

Psychiatry Res.

2009;173:107-112.

40.

Joe AY, Tielmann T, Bucerius J, et al. Response-dependent differences in regional cerebral blood flow changes with citalopram in treatment of major depression.

J Nucl Med.

2006;47:1319-1325.

41.

Langenecker SA, Kennedy SE, Guidotti LM, et al. Frontal and limbic activation during inhibitory control predicts treatment response in major depressive disorder.

Biol Psychiatry.

2007;62:1272-1280.

42.

Drevets WC, Bogers W, Raichle ME. Functional anatomical correlates of antidepressant drug treatment assessed using PET measures of regional glucose metabolism.

Eur Neuropsychopharmacol.

2002;12:527-544.

43.

Davies J, Lloyd KR, Jones IK, et al. Changes in regional cerebral blood flow with venlafaxine in the treatment of major depression.

Am J Psychiatry.

2003;160:374-376.

44.

Little JT, Ketter TA, Kimbrell TA, et al. Bupropion and venlafaxine responders differ in pretreatment regional cerebral metabolism in unipolar depression.

Biol Psychiatry.

2005;57:220-228.

45.

Milak MS, Parsey RV, Lee L, et al. Pretreatment regional brain glucose uptake in the midbrain on PET may predict remission from a major depressive episode after three months of treatment.

Psychiatry Res.

2009;173:63-70.

46.

Moore GJ, Cortese BM, Glitz DA, et al. A longitudinal study of the effects of lithium treatment on prefrontal and subgenual prefrontal gray matter volume in treatment-responsive bipolar disorder patients.

J Clin Psychiatry.

2009;70:699-705.

47.

Kimbrell TA, Little JT, Dunn RT, et al. Frequency dependence of antidepressant response to left prefrontal repetitive transcranial magnetic stimulation (rTMS) as a function of baseline cerebral glucose metabolism.

Biol Psychiatry.

1999;46:1603-1613.

48.

Eschweiler GW, Wegerer C, Schlotter W, et al. Left prefrontal activation predicts therapeutic effects of repetitive transcranial magnetic stimulation (rTMS) in major depression.

Psychiatry Res.

2000;99:161-172.

49.

Nahas Z, Teneback CC, Kozel A, et al. Brain effects of TMS delivered over prefrontal cortex in depressed adults: role of stimulation frequency and coil-cortex distance.

J Neuropsychiatry Clin Neurosci.

2001;13:459-470.

50.

Speer AM, Kimbrell TA, Wassermann EM, et al. Opposite effects of high and low frequency rTMS on regional brain activity in depressed patients.

Biol

Psychiatry.

2000;48:1133-1141.

51.

Kozel FA, Johnson KA, Nahas Z, et al. DTI measures of prefrontal cortex white matter microstructure after several weeks of daily left high frequency rTMS in outpatients with major depression.

J ECT.

In press.

52.

Nahas Z, Teneback C, Chae JH, et al. Serial vagus nerve stimulation functional MRI in treatment-resistant depression.

Neuropsychopharmacology.

2007;32:1649-1660.

53.

Zobel A, Joe A, Freymann N, et al. Changes in regional cerebral blood flow by therapeutic vagus nerve stimulation in depression: an exploratory approach.

Psychiatry Res.

2005;139:165-179.

54.

Conway CR, Sheline YI, Chibnall JT, et al. Cerebral blood flow changes during vagus nerve stimulation for depression.

Psychiatry Res

. 2006;146:179-184.

55.

McCormick LM, Boles Ponto LL, Pierson RK, et al. Metabolic correlates of antidepressant and antipsychotic response in patients with psychotic depression undergoing electroconvulsive therapy.

J ECT.

2007;23:265-273.

56.

Nobler MS, Oquendo MA, Kegeles LS, et al. Decreased regional brain metabolism after ECT.

Am J Psychiatry.

2001;158:305-308.

57.

Nobuhara K, Okugawa G, Minami T, et al. Effects of electroconvulsive therapy on frontal white matter in late-life depression: a diffusion tensor imaging study.

Neuropsychobiology.

2004;50:48-53.

58.

Dougherty DD, Weiss AP, Cosgrove GR, et al. Cerebral metabolic correlates as potential predictors of response to anterior cingulotomy for treatment of major depression.

J Neurosurg.

2003;99:1010-1017.

59.

Lozano AM, Mayberg HS, Giacobbe P, et al. Subcallosal cingulate gyrus deep brain stimulation for treatment-resistant depression.

Biol Psychiatry.

2008;64:461-467.

60.

Mayberg HS, Lozano AM, Voon V, et al. Deep brain stimulation for treatment-resistant depression.

Neuron.

2005;45:651-660.

61.

Schlaepfer TE, Cohen MX, Frick C, et al. Deep brain stimulation to reward circuitry alleviates anhedonia in refractory major depression.

Neuropsychopharmacology.

2008;33:368-377.

62.

Goldapple K, Segal Z, Garson C, et al. Modulation of cortical-limbic pathways in major depression: treatment-specific effects of cognitive behavior therapy.

Arch Gen Psychiatry.

2004;61:34-41.

63.

Kennedy SH, Konarski JZ, Segal ZV, et al. Differences in brain glucose metabolism between responders to CBT and venlafaxine in a 16-week randomized controlled trial.

Am J Psychiatry.

2007;164:778-788.

64.

Ebert D, Feistel H, Barocka A, Kaschka W. Increased limbic flow and total sleep deprivation in major depression with melancholia.

Psychiatry Res.

1994;55:101-109.

65.

Wu J, Buchsbaum MS, Gillin JC, et al. Prediction of antidepressant effects of sleep deprivation by metabolic rates in the ventral anterior cingulate and medial prefrontal cortex [published correction appears in

Am J Psychiatry.

1999;156:1666].

Am J Psychiatry.

1999;156:1149-1158.

66.

Volk SA, Kaendler SH, Hertel A, et al. Can response to partial sleep deprivation in depressed patients be predicted by regional changes of cerebral blood flow?

Psychiatry Res.

1997;75:67-74.

67.

Clark CP, Brown GG, Frank L, et al. Improved anatomic delineation of the antidepressant response to partial sleep deprivation in medial frontal cortex using perfusion-weighted functional MRI.

Psychiatry Res.

2006;146:213-222.